Terminated PHASE1 INTERVENTIONAL 1-arm NCT00747305

Sunitinib Before and After Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed By Surgery

Biomarkers of Tumor Angiogenesis and Response to Sunitinib Maleate in Renal Cell Carcinoma

Sponsor: Harry Drabkin

Interventions adjuvant therapy gene expression analysis immunohistochemistry staining method laboratory biomarker analysis neoadjuvant therapy reverse transcriptase-polymerase chain reaction sunitinib malate therapeutic conventional surgery western blotting

Updated 6 times since 2017 Last updated: Oct 21, 2015 Started: Oct 31, 2008 Primary completion: Jul 31, 2014 Completion: Jul 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Study terminated early due to low accrual.

Other Kidney Cancer trials with similar outcome

Browse all Kidney Cancer trials

Listed as NCT00747305, this PHASE1 trial focuses on Kidney Cancer and remains terminated or withdrawn. Sponsored by Harry Drabkin, it has been updated 6 times since 2008, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE1
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE1
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE1
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE1
Feb 2017 — Jun 2018 [monthly]

Terminated PHASE1

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Terminated PHASE1

First recorded

Oct 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Harry Drabkin

Data source: Medical University of South Carolina

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Charleston, United States